Key Highlights
- French pharmaceutical company Servier will purchase Day One Biopharmaceuticals (DAWN) at $21.50 per share in an all-cash transaction valued at approximately $2.5 billion
- The purchase price delivers a premium of roughly 68% over DAWN’s Thursday closing price and 86% above its 30-day volume-weighted average
- Shares of DAWN jumped approximately 66% during premarket hours on March 6, 2026, following the acquisition news
- Day One’s board of directors has given unanimous approval and recommends shareholders tender their shares
- Deal completion is anticipated for Q2 2026, pending regulatory approvals and shareholder participation
French pharmaceutical giant Servier has entered into a definitive agreement to purchase Day One Biopharmaceuticals (DAWN) for approximately $2.5 billion in cash. The announcement triggered a massive 66% surge in DAWN stock during Friday’s premarket session on March 6.
https://x.com/FenwickWest/status/2029944210065969265?s=20
Servier has committed to paying $21.50 for each outstanding Day One share. This acquisition price represents a significant 68% markup over Thursday’s closing level and stands 86% higher than the stock’s 30-day volume-weighted average trading price.
Day One Biopharmaceuticals, Inc., DAWN
The transaction structure eliminates financing contingencies, removing a typical barrier that frequently causes acquisition deals to collapse. The parties expect to finalize the deal during the second quarter of 2026, contingent upon receiving U.S. antitrust approval and achieving majority shareholder participation in the tender offer.
Day One’s board of directors conducted a thorough evaluation and unanimously decided to recommend that shareholders accept the tender offer. Standard protections include non-solicitation clauses and an $87.7 million termination fee payable under specific circumstances if the transaction fails to close.
Market observers weren’t entirely blindsided by the announcement. DAWN shares had already climbed on Wednesday amid takeover rumors, with Jazz Pharmaceuticals (JAZZ) and Ipsen (IPSEY) mentioned as potential acquirers at that time.
Strategic Value for Servier
The centerpiece of this acquisition is tovorafenib, Day One’s primary drug candidate designed to treat low-grade glioma — a brain tumor type. This therapy holds significant promise in pediatric oncology, the therapeutic area where Day One has concentrated its pipeline efforts.
For Servier, this acquisition strengthens its position in rare cancer treatments. The French pharmaceutical company, which generated €6.9 billion in revenues during fiscal 2024/25, currently reinvests approximately 20% of its branded product revenue into research and development. Integrating Day One’s portfolio aligns with Servier’s strategic objective to expand its footprint in targeted oncology therapeutics.
Transaction Framework
The acquisition follows an all-cash tender offer structure, with a subsequent merger step once all conditions are satisfied. Servier’s ability to proceed without securing additional financing strengthens deal certainty and execution probability.
The $87.7 million termination fee offers Day One shareholders some financial protection should the transaction fail to materialize under qualifying circumstances.
Before the acquisition announcement, Wall Street analysts had established a $17.00 price target on DAWN with a Buy rating — substantially below the agreed $21.50 acquisition price.
Day One’s market capitalization stood at roughly $1.35 billion before the deal was revealed. The $2.5 billion transaction value demonstrates the substantial premium Servier is willing to pay for access to Day One’s development pipeline.
Day One operates from its headquarters in Brisbane, California. Upon completion, the acquisition will transfer complete ownership to Servier, a privately-held French pharmaceutical company with products distributed across more than 130 countries worldwide.
